2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

12:00PM-2:00PM: Abstract Number: PP06

Learning to Self-Advocate in the Transition from Pediatric to Adult Lupus Care

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP12

Living a Full Life with A.S. Through Adaptations

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP03

Managing OsteoArthritis Pain with Daily Meditation

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP01

Physician, Patient, Person. Success in Balancing Multiple Roles Takes Support

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP07

Strengthening My Resiliency: How My Interprofessional Healthcare Team and I Improved My Management of Lupus

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP13

Support Groups and Patient Centred Care; Making a Difference in the Lives of People with Autoimmune and Rheumatic Conditions in Ghana

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP02

Sustained Weight Loss Managed by Multiple Medical Specialists

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP11

The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes

3S041 ACR/ARHP: Patient Perspectives Poster Session

12:00PM-2:00PM: Abstract Number: PP10

Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’

3S041 ACR/ARHP: Patient Perspectives Poster Session

2:30PM-4:00PM: Abstract Number: 891

A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 890

A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

3S087 ACR Abstract: RA–Treatments I: JAK Inhibitors (886–891)

2:30PM-4:00PM: Abstract Number: 848

A2A Adenosine Receptor Stimulation Switches TGF-β Signaling to Promote Chondrocyte Proliferation and Cartilage Regeneration

3S085 ACR Abstract: Osteoarthritis & Joint Biology–Basic Science (846–850)

2:30PM-4:00PM: Abstract Number: 900

Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study

3S089 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical I: Clinical Trials I (898–903)

2:30PM-4:00PM: Abstract Number: 862

Addressing the Pediatric Rheumatology Workforce Shortage: Results from the American College of Rheumatology Annual Pediatric Residents Program

3S081 ACR Abstract: Education (857–862)

2:30PM-4:00PM: Abstract Number: 857

An Interactive Rheumatology Curriculum for Interprofessional Teams Using a Novel Mobile App

3S081 ACR Abstract: Education (857–862)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].